HomeAbout
About

Retrotope is developing a new class of drugs designed to combat the disease and cellular degeneration that results from lipid peroxidation (LPO). By leveraging our unique insight into LPO and our proprietary technology platform, we have created a pipeline of first-in-class therapeutic candidates for the treatment of a range of devastating degenerative diseases.

Our lead drug candidate, RT001, is currently in late-stage clinical trials for the treatment of several orphan neurodegenerative diseases with few or no treatment options. This include amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), Friedreich’s ataxia (FA) and infantile neuroaxonal dystrophy (INAD).

Company Overview

IMPACT IN NUMBERS
50+
Addressable Diseases
10+
Research Programs
1
IND-Ready Programs
4
Clinical Programs
100+
Collaborators
25+
Research Institutions
100+
Patients Dosed
1000+
Patient/month of Drug Usage
Leadership
Anil Kumar, MBA,
President
Mikhail S. Shchepinov, PhD,
Founder and CSO
Peter G. Milner, MD,
CMO
Vidhya Gopalakrishnan, PhD,
CDO
Karsten Schmidt, PhD,
Senior VP, Ophthalmology
Rick E. Winningham, MBA,
Chairman
George Garibaldi, MD,
Director
Anil Kumar, MBA,
President and Director
Nitin Mehta, PhD, MBA,
Director
Mikhail S. Shchepinov, PhD,
Founder and CSO; Director
JOIN
OUR
TEAM

Retrotope is growing! We need talented and curious team members who want to make an impact on the future of science and therapeutics. To make this possible, Retrotope provides a vibrant and dynamic work environment in an exciting and meaningful industry.

JOIN
The study’s enrollment target of 40 patients was exceeded in less than six weeks, highlighting the high demand for participation in the trial featuring a novel treatment approach for ALS. Based on this rapid patient enrollment, Retrotope expects data from the trial to be available by the end of 2021.
Read more
Isotope-reinforced polyunsaturated fatty acids improve Parkinson’s disease-like phenotype in rats overexpressing α-synuclein
Read more
The study’s enrollment target of 40 patients was exceeded in less than six weeks, highlighting the high demand for participation in the trial featuring a novel treatment approach for ALS. Based on this rapid patient enrollment, Retrotope expects data from the trial to be available by the end of 2021.
Read more
Anil Kumar, Retrotope’s president and chief business officer, gave a corporate presentation as part of the 2021 BIO CEO & Investor Digital Conference. The presentation highlighted a busy year ahead for Retrotope with multiple key data readouts planned for its broad clinical-stage pipeline.
See more
FIND US
RETROTOPE,
4300 EL CAMINO REAL,
SUITE 201, LOS ALTOS,
CA 94022